Stay updated with breaking news from Beckley Psytech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GODALMING, UK / ACCESSWIRE / December 22, 2022 / Condor Gold Plc (AIM:CNR)(TSX:COG) announces that further to its announcement of 28 November 2022 the Company has today appointed Denham Eke as a Non-Executive
Insider's annual 100 People Transforming Business 2022 list is live. Here's the list of honorees in the healthcare sector.
Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023.ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, under clinical development for depression.ELE-101 is th...
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced that it has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited ("Eleusis") ...